 Endothelin Receptor Antagonists
"Endothelin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS.
| Descriptor ID |
D065128
|
| MeSH Number(s) |
D27.505.519.364
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Endothelin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Endothelin Receptor Antagonists".
This graph shows the total number of publications written about "Endothelin Receptor Antagonists" by people in this website by year, and whether "Endothelin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 1 | 3 | 4 | | 2009 | 1 | 2 | 3 | | 2010 | 1 | 2 | 3 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 2 | 2 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 1 | 3 | | 2016 | 0 | 3 | 3 | | 2017 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Endothelin Receptor Antagonists" by people in Profiles.
-
Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI. The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. Endocr Rev. 2020 04 01; 41(2).
-
Cartin-Ceba R, Krowka MJ. Pulmonary Complications of Portal Hypertension. Clin Liver Dis. 2019 11; 23(4):683-711.
-
Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin N, Savale L, Krowka M. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019 07; 7(7):594-604.
-
Ivy D, Wilson N. Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome. Circulation. 2019 01 02; 139(1):64-66.
-
Berger RMF, Gehin M, Beghetti M, Ivy D, Kusic-Pajic A, Cornelisse P, Grill S, Bonnet D. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol. 2017 08; 83(8):1734-1744.
-
Fussner LA, Krowka MJ. Current Approach to the Diagnosis and Management of Portopulmonary Hypertension. Curr Gastroenterol Rep. 2016 Jun; 18(6):29.
-
Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacol Rev. 2016 Apr; 68(2):357-418.
-
Kim JS, McSweeney J, Lee J, Ivy D. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension. Pediatr Crit Care Med. 2016 Mar; 17(3 Suppl 1):S89-100.
-
Trinity JD, Barrett-O'Keefe Z, Ives SJ, Morgan G, Rossman MJ, Donato AJ, Runnels S, Morgan DE, Gmelch BS, Bledsoe AD, Richardson RS, Wray DW. Endogenous endothelin-1 and femoral artery shear rate: impact of age and implications for atherosclerosis. J Hypertens. 2016 Feb; 34(2):266-73.
-
Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Gali? N, Ivy DD, Ja?s X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol. 2016 Jan 01; 202:52-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|